Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00376623
Status:
COMPLETED
Last Update Posted:
2022-06-21
First Post:
2006-09-14
Brief Title:
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
An Open Randomised Clinical Phase II Trial to Investigate the Efficacy Safety and Pharmacokinetics of a Single Dose of 200 mg of iv BI 2536 in Comparison to 50 mg of iv BI 2536 Administered on Days 1 2 and 3 in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial will be performed to evaluate whether BI 2536 may be effective in the treatment of advanced or metastatic NSCLC of stage IIIB or IV in patients who relapsed after or failed first-line therapy A secondary aim is to identify the most suitable dosage schedule for the further Phase II and III clinical programme of BI 2536 To achieve this objective two dosage schedules are compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None